To explore the relevance of their gene targets in ICB-induced tumor immunity, we first identified the 25 most common and unique gene targets of Phase I/Phase II/FDA-approved kinase inhibitors offered in a commercial screening library37-39 (ALK, AURKA, BTK, CSF1R, EGFR, FGFR1, FLT1, FLT3, IGF1, IGFR1, IKBKB, JAK1, JAK2, KDR, KIT, MET, MTOR, NTRK1, PDGFRA, PIKFYVE, PTK2, RAF1, RET, SRC, and SYK). This evidence concerns the gene FLT1 and neoplasm.